Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on developing the drug for a rare chronic ...

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

ADI-001 clinical development program now addresses six autoimmune diseases. Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be ...

Preconception predictors of adverse pregnancy outcomes among women with SLE include previous lupus nephritis, chronic hypertension, SLE disease activity, and APS.